These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 3167821)

  • 1. Reappraisal of the association between adriamycin and iron.
    Gelvan D; Samuni A
    Cancer Res; 1988 Oct; 48(20):5645-9. PubMed ID: 3167821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
    Schroeder PE; Hasinoff BB
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of adriamycin toxicity by iron chelates is not a free radical mechanism.
    Gelvan D
    Biol Trace Elem Res; 1997 Mar; 56(3):295-309. PubMed ID: 9197926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin controls oxidative stress and modulates iron, ferritin, and transferrin levels in adriamycin treated rats.
    Othman AI; El-Missiry MA; Amer MA; Arafa M
    Life Sci; 2008 Oct; 83(15-16):563-8. PubMed ID: 18793653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells.
    Berczi A; Barabas K; Sizensky JA; Faulk WP
    Arch Biochem Biophys; 1993 Jan; 300(1):356-63. PubMed ID: 8424669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transferrin, is a mixed chelate-protein ternary complex involved in the mechanism of iron uptake by serum-transferrin in vitro?
    Pakdaman R; Abdallah FB; El Hage Chahine JM
    J Mol Biol; 1999 Nov; 293(5):1273-84. PubMed ID: 10547300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric and cupric reductase activities by iron-limited cells of the green alga Chlorella kessleri: quantification via oxygen electrode.
    Weger HG; Walker CN; Fink MB
    Physiol Plant; 2007 Oct; 131(2):322-31. PubMed ID: 18251903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine metabolism and disposition of iron:adriamycin complexes.
    Egorin MJ; Clawson RE; Ross LA; Friedman RD; Reich SD; Pollak A; Bachur NR
    Cancer Res; 1983 Jul; 43(7):3253-62. PubMed ID: 6189594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
    Schroeder PE; Hasinoff BB
    Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of transferrin-iron by adriamycin at acidic pH.
    Demant EJ; Nørskov-Lauritsen N
    FEBS Lett; 1986 Feb; 196(2):321-4. PubMed ID: 3949004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of iron in solutions with the ferric-xylenol orange complex.
    Gay C; Collins J; Gebicki JM
    Anal Biochem; 1999 Sep; 273(2):143-8. PubMed ID: 10469483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent modifications of ferric-adriamycin.
    Gelvan D; Berg E; Saltman P; Samuni A
    Biochem Pharmacol; 1990 Apr; 39(8):1289-95. PubMed ID: 2157447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the extracellular pH, an inhibitor of Na+/H+ exchanger and an inhibitor of Cl-/HCO3-exchanger on adriamycin accumulation.
    Asaumi J; Kawasaki S; Nishikawa K; Kuroda M; Hiraki Y
    Anticancer Res; 1995; 15(1):71-5. PubMed ID: 7733644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry of dexrazoxane and analogues.
    Hasinoff BB
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of iron in adriamycin biochemistry.
    Myers C; Gianni L; Zweier J; Muindi J; Sinha BK; Eliot H
    Fed Proc; 1986 Nov; 45(12):2792-7. PubMed ID: 3533644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual role of Lys206-Lys296 interaction in human transferrin N-lobe: iron-release trigger and anion-binding site.
    He QY; Mason AB; Tam BM; MacGillivray RT; Woodworth RC
    Biochemistry; 1999 Jul; 38(30):9704-11. PubMed ID: 10423249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin and adriamycin-DNA nephrotoxicity in rats.
    Giroux L; Smeesters C; Boury F; Faure MP; Jean G
    Lab Invest; 1984 Feb; 50(2):190-6. PubMed ID: 6607380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.